25.5 C
Vientiane
Saturday, June 21, 2025
spot_img
Home Blog Page 1098

Delta Force Reveals Big Plans for 2025 Updates

New Release Windows for Mobile Version Announced

Los Angeles, Jan. 13, 2025 /PRNewswire/ — Today, Delta Force developer Team Jade revealed their plans for continuing content updates coming to the game in 2025, as well as gave an update on the release of the mobile version of Delta Force.

Delta Force has a bold plan for bringing its players fresh new content in 2025, including five new operators, seven new maps, new gadgets, new vehicles and more. For a full breakdown, please check out the Delta Force 2025 roadmap.

Team Jade will be sharing more when these seasons are dropping in the game soon, in the meantime, please visit the game’s official website for more information about Delta Force.

Team Jade also provided an update on the release window for the much anticipated mobile version of the game. In a message to Delta Force Players by Game Director Shadow Guo, the team is committed to delivering the top tier experience that players deserve, and to do that means moving the release of the mobile version to the Summer of 2025.

For more information about Delta Force visit our official website and YouTube channel, with additional updates found on X, Facebook, Instagram, and TikTok.

About Delta Force

Delta Force is the well-received free-to-play tactical shooter, serving as the next installment of the beloved Delta Force series. Featuring large-scale multiplayer modes, as well as an action-packed single-player/co-op campaign, a deep weapons arsenal for customization, and more, Delta Force can now be downloaded for free via its website, Delta Force on Steam and Epic Games Store pages.

About Team Jade

Team Jade is a notable branch of TiMi Studio Group renowned for Call of Duty: Mobile and Assault Fire, the latter being the most popular Chinese shooter game on PC for the past decade. With a roster of hundreds of industry veterans, the team has garnered multiple prestigious accolades, including BAFTA and TGA awards.

BingX Expands DeFi Access with Exclusive Launchpad for SOLV Token

PANAMA CITY, Jan. 13, 2025 /PRNewswire/ — BingX, a global leading cryptocurrency exchange, has announced the launch of SOLV token from Solv Protocol on BingX Launchpad. The subscription for the SOLV token will officially open on January 16, 2025, and the token will be listed on the BingX spot market at 18:00 (GMT+8) on January 17, 2025.

BingX Expands DeFi Access with Exclusive Launchpad for SOLV Token
BingX Expands DeFi Access with Exclusive Launchpad for SOLV Token

Solv Protocol is a decentralized finance (DeFi) platform designed to unlock the liquidity of Bitcoin and other digital assets within the DeFi ecosystem. It has quickly gained prominence in the cryptocurrency space by offering innovative solutions that enhance the utility of Bitcoin and other crypto assets. As the exclusive launchpad for SOLV, BingX offers unique access to participate in SOLV token distribution and trading. It allows BingX users to explore varied yield opportunities without sacrificing liquidity, enabling easy integration of Bitcoin into the DeFi ecosystem.

The total subscription pool for the Solv Protocol Launchpad is 4 million SOLV tokens. All BingX users are eligible to participate in the subscription, with each user guaranteed a successful subscription. The final individual subscription quota is directly proportional to the average amount of assets held by the user between January 13th and January 16th, based on asset snapshots. The individual winning limit is set at 20,000 SOLV tokens. Meanwhile, users can increase this limit by inviting friends to join. For each successful referral, both the user and their invited friend will benefit from an enhanced limit.

As part of the rewards program, BingX users can also participate in the exclusive “Learn to Earn” SOLV campaign. BingX users can complete Solv Protocol quizzes, make SOLV deposits, trade SOLV, and invite friends to earn a share of the 500,000 SOLV prize pool. New users who sign up on BingX are also eligible to receive airdrops. Furthermore, one lucky participant will win a lottery and receive a 20,000 SOLV airdrop.

“We are excited to launch the SOLV token on BingX Launchpad, marking a significant milestone in empowering our users with unparalleled access to innovative DeFi solutions.” Vivien Lin, Chief Product Officer at BingX, commented: “At BingX, we are committed to offering opportunities for our community to engage with groundbreaking blockchain projects. Through BingX Launchpad, we hope to shine a light on promising projects and help bring game-changing innovations to a global audience.”

BingX Launchpad is a cutting-edge platform faciliating the launch of early-stage crypto projects. It offers structured token distribution, global audience engagement, and rapid growth. By leveraging BingX’s expertise and network, it ensures projects reach the market efficiently.

About BingX
Founded in 2018, BingX is a leading crypto exchange, serving over 10 million users worldwide. BingX offers diversified products and services, including spot, derivatives, copy trading, and asset management – all designed for the evolving needs of users, from beginners to professionals. BingX is committed to providing a trustworthy platform that empowers users with innovative tools and features to elevate their trading proficiency. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports.

For more information please visit: https://bingx.com/

Luzerne’s Craftsmanship Helps Dehua Ceramic Trade Association (China) Secure Guinness World Records Title for Largest Porcelain Car Sculpture (supported)

SINGAPORE, Jan. 13, 2025 /PRNewswire/ — Luzerne Pte Ltd is proud to announce its crucial role in helping the Dehua Ceramic Trade Association (China) secure the GUINNESS WORLD RECORDS™ title for producing the largest porcelain sculpture of a car (supported). Guinness World Records is the global authority on record-breaking achievements, with strict criteria for titles, including measurability, standardisation, verifiability, and the requirement to be the best in the world.

Selina Tang, CEO, with Luzerne staff celebrating the Guinness World Records™ title for the Largest Porcelain Car Sculpture (Supported), achieved in collaboration with the Dehua Ceramic Trade Association (China).
Selina Tang, CEO, with Luzerne staff celebrating the Guinness World Records™ title for the Largest Porcelain Car Sculpture (Supported), achieved in collaboration with the Dehua Ceramic Trade Association (China).

On 14 August 2024, Luzerne’s craftsmanship officially broke the record for producing the world’s first car model fully sculpted in porcelain on a scale of 1:1 and weighing in at an impressive 1.4 tonnes. According to officials from Guinness World Records, onsite measurements of the car show a body length of 5.51 metres, a width of 2.15 metres and a height of 1.39 metres, giving a combined measurement of 9.05 metres. This exceeds the minimum requirement of 8 metres for an entry in this category, thereby being listed officially in the Guinness World Records Hall of Fame.

In collaboration with the Dehua Ceramic Trade Association in China, Luzerne Pte Ltd spent 11 months accomplishing this feat in its wholly-owned factory situated in the county. Dehua, Fujian province, China, is the birthplace of Blanc de Chine, a name given to porcelain celebrated for its soft ivory-white hue, which is also manifested on the car’s exterior. In 2021, the kilns of Dehua were inscribed on the UNESCO World Heritage List. The Chinese government had also conferred it the honour of the National Civilised City Award (NCCA) to boost its development and status as the World’s Porcelain City.

The feat is also a significant testament to the craftsmanship of the 50 craftsmen who worked on the project. The sheer size of the sculpture and its complicated form have thus added to the difficulty of this challenge. “The team of 50 boasts diverse skillsets, so we benefited greatly from teamwork to accomplish this feat; it is impossible to do it alone. Dehua is the world’s porcelain city and we have a mission to spread its name afar,” explained Mr Peter Lek, Managing Director of Hiap Huat Holdings Pte Ltd and Chairman of Luzerne Pte Ltd.

The Dehua county government also elaborated that it will continue exploring new inroads in ceramic culture and art, breaking frontiers in its global recognition and raising market competitiveness. This is in its overall vision of using Blanc de Chine as a conversation intermediary with the rest of the world.

About Luzerne

Luzerne has been designing and producing bespoke quality tableware for some of the world’s most renowned restaurants, hotels and chefs since 2004. We pioneered the creation of fine china without animal bone ash, and the Luzerne factory in Dehua is the first in the world to be Halal-certified. We are also humbled to be named the Century Best Brand in China in 2019.

Drawing on over 75 years of expertise, we became Singapore’s first tableware manufacturer to develop its own line of products and produces up to 28 million pieces of ceramic and stone tableware annually at our fully-automated factory in Dehua. Our strategic location in Dehua, China comes as no surprise for the charming county is historically the birthplace of Blanc de Chine Dehua also holds several accolades such as The World Porcelain City and The National Civilised City Award conferred by the Chinese government. In 2021, its kilns were ceremoniously inscribed on the UNESCO World Heritage List.

Luzerne’s global presence in over 60 countries is supported by 800 employees in 5 offices in China (Shanghai, Xiamen, Dehua), Cambodia, and our headquarters in Singapore. Luzerne tableware is used in restaurants and hotels globally, and can also be experienced in the skies with Singapore Airlines. It is the preferred brand with renowned hospitality chains.

For more information, please visit www.luzerne.com.

About Guinness World Records

Guinness World Records™ is the global authority on record-breaking achievements. Established in 1955, the organisation has become synonymous with documenting extraordinary feats, unique talents, and remarkable accomplishments across the world. With a mission to celebrate the best in human endeavour and to inspire people of all ages, cultures, and nationalities, Guinness World Records™ continues to push the boundaries of what is possible.

Each year, millions of people attempt to break records, and only the most extraordinary are awarded the official Guinness World Records™ title. From awe-inspiring human achievements to groundbreaking technological advancements, Guinness World Records™ recognises and honours the incredible potential of individuals, teams, and organisations worldwide.

For more information, please visit www.guinnessworldrecords.com.

Gianna Lullume Baby Soother Device Officially Launches on Kickstarter

HONG KONG, Jan. 13, 2025 /PRNewswire/ — Gianna Lullume, an innovative brand committed to improving infant sleep and promoting family well-being, is proud to announce the official launch of its crowdfunding campaign on Kickstarter. Designed for infants and toddlers aged 0-4, the Gianna Lullume Baby Soother Device offers a cutting-edge solution to one of parenting’s most significant challenges: sleepless nights.

Gianna Lullume Baby Soother Device
Gianna Lullume Baby Soother Device

https://www.kickstarter.com/projects/giannalullumesoother/gianna-baby-soother-with-cry-detection

This advanced sleep device integrates cry detection technology, sound therapy, and red-light therapy to create a soothing, smart sleep environment. The result? Better sleep for babies and peace of mind for parents.

Key Features:

  • Cry Detection Technology: Detects a baby’s cry within 20 seconds and automatically responds with calming sounds and lights to soothe the baby before their distress escalates.
  • Red Light Therapy: Scientifically designed red light promotes melatonin production, supporting natural sleep cycles without disrupting the baby’s rest.
  • Sound Therapy: Offers a variety of soothing options, including white noise, pink noise, nature sounds, and womb-like heartbeats, all optimized for infant relaxation and safety.
  • Smart App Control: Enables parents to remotely manage settings, timers, and notifications, ensuring convenience and customization.

“At Gianna Lullume, we believe that a better sleep for babies translates to a better sleep for the entire family,” said Simon Shawn, CEO of Gianna. “Our mission is to equip parents with intelligent tools that bring comfort to their little ones while fostering a calm and restful home environment.”

Join the Movement

The Kickstarter campaign is now live, offering exclusive early-bird rewards for backers who choose to join the mission to redefine sleep for families worldwide. Supporters can visit the campaign page at Kickstarter to learn more about the product and secure special launch perks.

About Gianna Lullume

Founded with the vision of improving the lives of families through science-backed sleep solutions, Gianna Lullume specializes in innovative devices designed to support infants and toddlers. By combining thoughtful design, advanced technology, and a deep understanding of parental needs, Gianna Lullume aims to make restful nights a reality for families everywhere.

Sleepless or Restless?Soothing Your Little One with Gianna Lullume.

For media inquiries, please contact:
market@giannashop.com

Gianna Branding Team
brand@kerchangroup.com 

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ — Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.

Cooperation of Simcere Zaiming and Abbvie
Cooperation of Simcere Zaiming and Abbvie

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma”

“SIM0500 is developed via Simcere Zaiming’s proprietary T-cell engager platform,” said Renhong Tang, PhD, CEO of Simcere Zaiming. “We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. ”

Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory

About AbbVie in Oncology

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie’s Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

About Simcere Zaiming

Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, “Simcere”). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.

LG Innotek Reasserts Its Leadership in the Future Mobility Market at CES 2025

  • Exhibition booth attracts 65,000 cumulative visitors, showcasing innovative mobility components
  • Innovative technologies presented through a ‘User-Centric storytelling’ approach elicit strong acclaim, inquiries from visiting customers ensue

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — On the 13th, LG Innotek (CEO Moon Hyuksoo) announced that it successfully staged its exhibition at CES 2025 held in Las Vegas, USA.

Visitors at LG Innotek's CES 2025 Exhibition Booth
Visitors at LG Innotek’s CES 2025 Exhibition Booth

Situated at the entrance of the West Hall of the Las Vegas Convention Center (LVCC), LG Innotek’s exhibition booth attracted a steady stream of visitors from its opening on the first day of the CES event, on January 7th (local time).

Visitors at LG Innotek's CES 2025 Exhibition Booth
Visitors at LG Innotek’s CES 2025 Exhibition Booth

During the four-day exhibition period that lasted until the 10th, more than 65,000 visitors were recorded at the LG Innotek booth. Many visitors showed great interest, leading to product inquiries and on-the-spot meeting requests.

A company representative said, “This year, we prominently displayed a 1,800-inch large-scale video advertisement in the Main Hall of the West Hall and a 9-meter-tall banner at the booth entrance, effectively enhancing brand awareness and exhibition promotion.”

At CES 2025, LG Innotek focused its exhibition on the theme of mobility to solidify its position as a ‘Total Solution Provider’ in the global market for future mobility.

In particular, LG Innotek designed its open booth with a sleek, futuristic black aesthetic, showcasing not only a future vehicle mockup but also its new brand identity, ‘ENABLE THE NEXT’, and the slogan, ‘YOUR ASPIRATION, OUR INNOVATION.’

At the center of the exhibition booth, the future vehicle mockup displayed 15 key components for sensing, communication, and lighting. Additionally, the high-value vehicle lighting module, Nexlide A+, which won the CES 2025 Innovation Award, garnered significant attention.

LG Innotek Nexlide showcased at CES 2025
LG Innotek Nexlide showcased at CES 2025

In the expanded private booth, which was 30% larger than the previous year, various innovative and integrated solutions combining optical, communication, and automotive technologies were presented through an immersive User-Centric storytelling approach, receiving positive feedback.

Among these, the RGB-IR In-Cabin Camera Module, unveiled for the first time at CES 2025, stood out. This camera can monitor driver conditions, such as detecting drowsiness, and alert the driver immediately.

An LG Innotek employee demonstrating the In-Cabin Camera Module at CES 2025
An LG Innotek employee demonstrating the In-Cabin Camera Module at CES 2025

Unlike conventional models, this new module features a 150-degree field of view, enabling simultaneous monitoring of the driver, front passenger, and rear passengers. It integrates a 5-megapixel RGB camera, an IR camera for low-light environments, and a 3D camera that supports facial recognition for functions like login and payment.

When a driver logs in using facial recognition, settings such as radio channels and air conditioning levels, adjusted by previous drivers, are automatically switched to the new driver’s preferences. A North American customer said, “It’s impressive how such advanced features, which enhance convenience for drivers, are incorporated into a single small camera module.”

The innovation of ‘Nexlide Vision,’ developed with LG Innotek’s proprietary vehicle lighting technology, also drew attention. Combining pixel lighting and smart film technology, this product can implement pixels, surfaces, and lines simultaneously.

For instance, by writing a desired message on the adjacent pad, the text instantly appears on the vehicle’s lighting grill. This innovative application demonstrated how advanced communication capabilities can be integrated into vehicle lighting.

A customer who experienced Nexlide Vision’s lettering feature said, “If an emergency stop is required while driving, it’s possible to use Nexlide Vision to communicate specific reasons to following vehicles, potentially preventing accidents. LG Innotek’s technology is truly remarkable.”

Furthermore, LG Innotek’s comprehensive lineup of mobility solutions, including the Next-Generation Digital Key Solution, Vehicle AP Module, All-Weather Camera Solution, and the groundbreaking B-Link, which combines a wireless Battery Management System (BMS) with a Battery Junction Box (BJB), were prominently showcased at CES 2025.

CEO Moon Hyuksoo stated, “Through CES 2025, LG Innotek has further strengthened its position as a leader in future mobility components. We will continue to deliver innovative solutions that provide differentiated value to customers and grow as the reliable technology partner enabling our customer’s aspiration.”

LG Innotek CEO Moon Hyuksoo
LG Innotek CEO Moon Hyuksoo

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

– Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine
– Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields. However, concerns remain about the limitations of the technology, including the need for ultra-cold storage and side effects associated with lipid nanoparticles (LNP) required for mRNA delivery.

Recently, new platforms are emerging as alternatives to mRNA vaccines.

One such platform is the Virus-Like Particle (VLP) vaccine technology. While not as widely known as mRNA vaccines, Ferritin based nano platform VLP vaccines have been noted for their potential to significantly enhance immune responses due to their structural stability. VLPs mimic the structural characteristics of target viruses, presenting antigens in a virus-like configuration. Particularly, the Ferritin based nano platform VLP vaccine is being evaluated as a powerful platform capable of accommodating multiple virus antigens simultaneously, making it suitable for addressing various mutations.

DXVX(180400) has recently acquired global development rights from Stanford University for an innovative universal coronavirus vaccine based on the Ferritin based nano platform VLP technology. Through the dedication and persuasive efforts of Chong-Yoon Lim, Chairman of the COREE Group and major shareholder of DXVX, this collaboration was established.

Ferritin, a protein that stores iron, can self-assemble into hollow spherical nanoparticles depending on pH conditions. Dx&Vx’s VLP vaccine utilizes this ferritin-based nanoparticle platform to display the spike protein of the coronavirus on its surface, making a universal coronavirus vaccine. The Ferritin-based VLP vaccine structurally mimics the size and shape of the COVID-19 virus, enabling the immune system to recognize it as the actual virus. This VLP vaccine can induce a strong cytotoxic T-cell response, effectively combating viral infections.

The human immune system defends against viral infections through both humoral and cellular immune responses, a process known as ‘cross-presentation.’ Vaccines that stimulate both immune systems simultaneously provide more robust and long-lasting immunity compared to vaccines that only induce antibody production.

Cytotoxic T cells, which play a critical role in destroying virus-infected or cancerous cells, do not directly recognize antigens. Instead, T cells only identify antigen fragments presented by major histocompatibility complex (MHC) molecules, thereby targeting and eliminating infected cells.

Notably, Dx&Vx’s vaccine is designed to strongly induce both humoral and cellular immune responses, making it superior to traditional antigen protein-based vaccines that primarily focus on humoral immunity. The Ferritin-based VLP vaccine, now preparing for global Phase 2 clinical trials, is expected to demonstrate superior immune induction effects compared to marketed vaccines.

VLP vaccine image
VLP vaccine image

According to animal studies conducted by the Walter Reed Army Institute of Research (WRAIR), the Ferritin-based VLP vaccine demonstrated neutralizing antibody levels more than ten times higher than those of mRNA vaccines. Additionally, the Wuhan Institute of Virology in China reported that the Ferritin-based VLP vaccine outperformed mRNA vaccines. Collectively, these findings indicate that the Ferritin-based VLP vaccine may offer superior protective effects compared to traditional vaccine platforms.

Moreover, this vaccine has demonstrated stability at room temperature for up to two weeks and has shown the ability to induce strong immune responses even in previously unexposed organisms. These characteristics distinguish it from mRNA-based vaccines. The platform has also been validated for its applicability in polyvalent vaccines for broad mutation coverage, offering versatility in administration routes and various other advantages.

Ferritin-based vaccine can simultaneously activate both humoral and cellular immunity, whereas traditional vaccines primarily depend on humoral immunity (Global Journal ‘Vaccines’, December 2024)
Ferritin-based vaccine can simultaneously activate both humoral and cellular immunity, whereas traditional vaccines primarily depend on humoral immunity (Global Journal ‘Vaccines’, December 2024)

Dx&Vx’s VLP universal coronavirus vaccine has already completed Phase 1 clinical trials in the United States and South Africa, where it was evaluated against mRNA vaccines for antibody titers and adverse effects. The results have confirmed the technological superiority of this vaccine platform.

The Ferritin platform-based VLP vaccine is expected to be extended for the development of vaccines against various lethal viruses, such as influenza and Ebola, playing a critical role in future pandemic responses.

A Dx&Vx representative stated, “The ultimate goal of the Ferritin platform-based VLP vaccine under development is to provide a safe, superior, and convenient vaccine that offers maximum protection against various deadly infectious diseases for humanity.”

Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion

VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ — WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed by WAT for weight and health management. The study revealed that electroacupuncture may help improve exercise performance and post-exercise recovery by reducing heart rate and perceived exertion during physical activity.

Published in the International Journal of Environmental Research and Public Health, the study highlights the potential benefits of this neuromodulation technology based on traditional Chinese medicine technique for enhancing participation in physical activity.

The research involved 32 healthy participants, who underwent electroacupuncture sessions targeting the PC6 acupuncture point over the course of one week. The study employed the YMCA submaximal bike test to measure cardiovascular responses, including heart rate, systolic blood pressure, and perceived exertion levels.

Key findings included a significant reduction in heart rate during the most challenging stage of the exercise test, as well as a decreased perception of effort across all stages. Additionally, participants experienced quicker post-exercise recovery, with systolic blood pressure notably lower five minutes after completing the test. The proposed mechanism of action is through the modulation of the rostral ventrolateral medulla (RVLM), a key area in the brainstem that regulates cardiovascular function and arterial blood pressure.

The study suggests that electroacupuncture could be particularly useful for populations struggling with sedentary lifestyles or exercise-induced fatigue. By making exercise feel easier, this technique could encourage greater adherence to fitness routines, promoting better long-term health outcomes.

Possible application in hypertension management could also be explored in future studies, as the proposed mechanism has the potential to down-regulate the sympathetic nervous system and reduce blood pressure.

References:

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11507089/
  2. www.watmedical.com
  3. www.emeterm.com